pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

885 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT786Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand
    French vaccine maker Valneva is laying off 10% to 15% of its workforce and reducing revenue projections due to "an emerging adverse trend in travel vaccine uptake across key markets." The drugmaker
    Endpoints · 2mo ago↗ source
  • <![CDATA[Future Directions in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mC…
    onclive · 2mo ago↗ source
  • <![CDATA[Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharm…
← prev
page 25 of 36
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago↗ source
  • <![CDATA[Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (…
    onclive · 2mo ago↗ source
  • <![CDATA[Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant…
    onclive · 2mo ago↗ source
  • <![CDATA[Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castr…
    onclive · 2mo ago↗ source
  • <![CDATA[Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer…
    onclive · 2mo ago↗ source
  • <![CDATA[Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate canc…
    onclive · 2mo ago↗ source
  • <![CDATA[Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus o…
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Recommendations Address Key Controversies in Lymphoma Management]]>
    <![CDATA[Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on t…
    onclive · 2mo ago↗ source
  • <![CDATA[Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining…
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors ]]>
    <![CDATA[Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors. ]]>
    onclive · 2mo ago↗ source
  • Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
    Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech,…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD ]]>
    <![CDATA[Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.]]>
    onclive · 2mo ago↗ source
  • Post-Hoc: Why FDA Commissioner Marty Makary was ousted
    Marty Makary never stood a chance. Over the last few days, the now-former FDA commissioner had been left to twist in the wind, after headlines emerged late last week that President Donald Trump h…
    Endpoints · 2mo ago↗ source
  • <![CDATA[FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL. ]]>
    onclive · 2mo ago↗ source
  • Behind Galapagos’ transformation into Lakefront Biotherapeutics
    CHICAGO — From a 22nd-floor office overlooking the Chicago Riverwalk, in the heart of the Midwest hub’s white-collar downtown district, Lakefront Biotherapeutics’ executives hope to stage the compa…
    Endpoints · 2mo ago↗ source
  • <![CDATA[UCSF Receives Major Gift to Advance Research and Modernization]]>
    <![CDATA[Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer]]>
    <![CDATA[The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline check…
    onclive · 2mo ago↗ source
  • <![CDATA[CLL-321 Trial Efficacy and Safety Results Analysis]]>
    <![CDATA[Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.]]>
    onclive · 2mo ago↗ source
  • #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapy
    BOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…
    Endpoints · 2mo ago↗ source
  • <![CDATA[How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCO ]]>
    <![CDATA[Drs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[BRUIN CLL-321 Trial Impact and Treatment Selection]]>
    <![CDATA[Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy]]>
    <![CDATA[Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.]]>
    onclive · 2mo ago↗ source